Dr. Yi Chen
Recent Quotes
"INO's Zika virus vaccine success further validates the SynCon platform; we reiterate our Buy rating."
—
Dr. Yi Chen, H.C. Wainwright & Co.
(2/18/16)
more >
"The FDA cleared the clinical trial of INO's MERS vaccine, GLS-5300."
—
Dr. Yi Chen, H.C. Wainwright & Co.
(11/20/15)
more >
"INO's VGX-3100 could present a safe and non-surgical therapeutic option for CIN2/3."
—
Dr. Yi Chen, H.C. Wainwright & Co.
(9/22/15)
more >
"INO's cash balance should provide a runway to the end of 2018."
—
Dr. Yi Chen, H.C. Wainwright & Co.
(8/11/15)
more >
"INO announced a collaboration with the EORTC to evaluate INO-3112 for cervical cancer."
—
Dr. Yi Chen, H.C. Wainwright & Co.
(7/24/15)
more >
"INO initiated a Phase 1 trial to evaluate INO-4212 for Ebola."
—
Dr. Yi Chen, H.C. Wainwright & Co.
(5/13/15)
more >
"INO initiated a Phase 1 trial in chronic hepatitis B patients."
—
Dr. Yi Chen, H.C. Wainwright & Co.
(4/22/15)
more >
"We view DARPA's grant as a validation of INO's technology platform."
—
Dr. Yi Chen, H.C. Wainwright & Co.
(4/9/15)
more >
